COMPANY

InduPro, Inc.

InduPro is developing selective targeting therapeutics by leveraging tumor associated proximity antigens (TAPAs). From company website Source · Oct 12, 2026

Keywords: tumor Head and Neck Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma Squamous Cell Carcinoma of the Cervix Non Squamous Non Small Cell Lung Cancer Squamous Cell Carcinoma of the Esophagus Squamous Cell Carcinoma of the Anus Squamous Cell Carcinoma IDP-001

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $77M · announced Aug 12, 2026 Company release ↗
Source quote
- Aug 12, 2026 · Company release ↗
  “— InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a $77 million Series B”
Deal Lilly deal · amount not disclosed · announced Jan 7, 2026 Company release ↗
Source quote
- Jan 7, 2026 · Company release ↗
  “SEATTLE and CAMBRIDGE, MA— January 7, 2026 — InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a global strategic collaboration and licensing agreement”
Raise Strategic · amount not disclosed · announced Dec 10, 2025 Company release ↗
Source quote
- Dec 10, 2025 · Company release ↗
  “SEATTLE, WA and CAMBRIDGE, MA— December 10, 2025 — InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a strategic equity investment and research collaboration with”

Raises announced in these releases: $77M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Aug 12, 2026 Raise Series B · $77M source ↗
Jul 8, 2026 Trial start Phase 1/Phase 2: A Study of IDP-001 in Advanced or Metastatic Solid Tumors source ↗
Dec 10, 2025 Raise Strategic · amount not disclosed source ↗

Upcoming milestones

2028-06 (ESTIMATED) · Phase 1/Phase 2 · A Study of IDP-001 in Advanced or Metastatic Solid Tumors · NCT07602842

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07602842	A Study of IDP-001 in Advanced or Metastatic Solid Tumors	Phase 1/Phase 2	Recruiting	Jul 8, 2026	2028-06 (estimated)